Wedbush cut shares of Zalicus (NASDAQ:ZLCS) from an outperform rating to a neutral rating in a research report sent to investors on Tuesday morning, Analyst Ratings Net reports. The firm currently has $1.20 price target on the stock.
Separately, analysts at Oppenheimer downgraded shares of Zalicus from an outperform rating to a market perform rating in a research note to investors on Monday. They now have a $12.00 price target on the stock. Five analysts have rated the stock with a hold rating, The company presently has a consensus rating of Hold and an average price target of $3.74.
Shares of Zalicus (NASDAQ:ZLCS) traded up 5.36% during mid-day trading on Tuesday, hitting $1.18. 1,814,911 shares of the company’s stock traded hands. Zalicus has a 1-year low of $1.09 and a 1-year high of $8.28. The stock has a 50-day moving average of $4.72 and a 200-day moving average of $3.9. The company’s market cap is $26.1 million.
Zalicus (NASDAQ:ZLCS) last announced its earnings results on Monday, November 4th. The company reported ($0.46) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.50) by $0.04. Analysts expect that Zalicus will post $-1.74 EPS for the current fiscal year.
Zalicus Inc, formerly CombinatoRx, Incorporated, is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain and inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.